SARS-CoV-2

[Cellular & Molecular Immunology] Investigators showed that ACE2-overexpressing A549 cell-derived microparticles were a potential therapeutic agent against SARS-CoV-2 infection.

[International Journal of Biological Sciences] Scientists summarize the physiological and pathological damage of SARS-CoV-2 to these systems and its molecular mechanisms followed by clinical manifestation.

[Science Signaling] The authors reported that inhibitor of DNA binding protein 2 negatively regulated antiviral innate immune responses.

[Cellular & Molecular Immunology] Investigators reported the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a virus-like particle bearing a SARS-CoV-2 spike protein vaccine candidate formulated with or without Adjuvant System 03 or cytidine-phospho-guanosine 1018.

[Signal Transduction and Targeted Therapy] Scientists showed that SARS-CoV-2-triggered mast cells degranulation initiated alveolar epithelial inflammation and lung injury.

[Biomedicine & Pharmacotherapy] The authors provide an overview of the pathways involved with cardiomyocyte in COVID-19 subjects to help promoting pharmacotherapies that can protect against SARS-CoV-2-induced cardiac injuries.